Richard B Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1508288/publications.pdf

Version: 2024-02-01

273 papers	30,304 citations	4942 84 h-index	4870 168 g-index
293 all docs	293 docs citations	293 times ranked	26236 citing authors

#	Article	IF	Citations
1	Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights. CJC Open, 2022, 4, 56-64.	0.7	3
2	High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor Î± antagonists. Scientific Reports, 2022, 12, 1185.	1.6	22
3	Correspondence: Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1*05 Carriage is Associated with Anti-Drug Antibody Formation in Patients with Inflammatory Bowel Disease â€“ Is HLADQA1*05 gone before itâ€™s here?. Gastroenterology, 2022, , .	0.6	0
4	Impact of pretreatment dihydropyrimidine dehydrogenase genotypeâ€guided fluoropyrimidine dosing on chemotherapy associated adverse events. Clinical and Translational Science, 2021, 14, 1338-1348.	1.5	27
5	Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment. Annals of Internal Medicine, 2021, 174, 432.	2.0	2
6	Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort Study. Clinical and Translational Gastroenterology, 2021, 12, e00332.	1.3	7
7	Pharmacokinetics of a onceâ€daily tacrolimus formulation in first nations and caucasian liver transplant recipients. Transplant International, 2021, 34, 2266-2273.	0.8	1
8	Pharmacogenomicâ€based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system. Clinical and Translational Science, 2021, 14, 2231-2241.	1.5	8
9	Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: In Vitro Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates. Frontiers in Pharmacology, 2021, 12, 713567.	1.6	10
10	Association of Baclofen With Falls and Fractures in Patients With CKD. American Journal of Kidney Diseases, 2021, 78, 470-473.	2.1	4
11	Mouse NTCPâ€“Mediated Rosuvastatin Uptake In Vitro and in Slc10a1-Deficient Mice. AAPS Journal, 2021, 23, 17.	2.2	1
12	In-vitro characterization of coding variants with predicted functional implications in the efflux transporter multidrug resistance protein 4 (MRP4, ABCC4). Pharmacogenetics and Genomics, 2021, Publish Ahead of Print, .	0.7	2
13	Near Miss or Standard of Care? DPYD Screening for Cancer Patients Receiving Fluorouracil. Current Oncology, 2021, 28, 94-97.	0.9	1
14	Letter: genetic variation in the HLAâ€DQA1*05 allele predicts tumour necrosis factorâ€Î± antagonist immunogenicity â€“ does location matter?. Alimentary Pharmacology and Therapeutics, 2021, 53, 1055-1056.	1.9	1
15	Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. Journal of Thrombosis and Thrombolysis, 2020, 49, 294-303.	1.0	37
16	HLADQA1*05 genotype predicts antiâ€drug antibody formation and loss of response during infliximab therapy for inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2020, 51, 356-363.	1.9	60
17	Rosuvastatin Myotoxicity After Starting Canagliflozin Treatment: A Case Report. Annals of Internal Medicine, 2020, 173, 585-587.	2.0	13
18	Genetic variation in the farnesoid X-receptor predicts Crohnâ€™s disease severity in female patients. Scientific Reports, 2020, 10, 11725.	1.6	8

#	Article	IF	Citations
19	Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1728-1739.	2.2	1
20	Covid-19 in Critically Ill Patients in the Seattle Region â€" Case Series. New England Journal of Medicine, 2020, 382, 2012-2022.	13.9	2,120
21	Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients. Breast Cancer Research and Treatment, 2020, 183, 365-372.	1.1	9
22	Attenuation of bile acid-mediated FXR and PXR activation in patients with Crohnâ€™s disease. Scientific Reports, 2020, 10, 1866.	1.6	40
23	In Vitro Functional Characterization and in Silico Prediction of Rare Genetic Variation in the Bile Acid and Drug Transporter, Na⁺-Taurocholate Cotransporting Polypeptide (NTCP,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50	2.3	14
24	Letter: immunogenicity of infliximabâ€"ready for routine prediction? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 813-814.	1.9	0
25	Baclofen has a risk of encephalopathy in older adults receiving dialysis. Kidney International, 2020, 98, 979-988.	2.6	12
26	The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics. Cold Spring Harbor Perspectives in Medicine, 2019, 9, a033027.	2.9	49
27	Crohnâ€™s Disease Is Associated with Decreased CYP3A4 and P-Glycoprotein Protein Expression. Molecular Pharmaceutics, 2019, 16, 4059-4064.	2.3	16
28	Precision Medicine: Lessons Learned From Implementation of a Pharmacogeneticsâ€Based Patient Care Program in a Realâ€World Setting. Clinical Pharmacology and Therapeutics, 2019, 106, 933-935.	2.3	5
29	Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1. Drug Metabolism and Disposition, 2019, 47, 832-842.	1.7	41
30	Targeted next generation sequencing as a tool for precision medicine. BMC Medical Genomics, 2019, 12, 81.	0.7	54
31	Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation. Journal of the American Geriatrics Society, 2019, 67, 1902-1906.	1.3	19
32	DPYD and Fluorouracil-Based Chemotherapy: Mini Review and Case Report. Pharmaceutics, 2019, 11, 199.	2.0	65
33	Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. Clinical Pharmacokinetics, 2019, 58, 1077-1089.	1.6	12
34	Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients. Oral Oncology, 2019, 89, 72-78.	0.8	28
35	Effect of <scp>CYP</scp>4F2,<scp>VKORC</scp>1, and <scp>CYP</scp>2C9 in Influencing Coumarin Dose: A Singleâ€Patient Data Metaâ€Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 2019, 105, 1477-1491.	2.3	23
36	Apixaban and RosuvasÂÂtatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2018, 46, 485-492.	1.7	22

#	Article	IF	Citations
37	<scp>HLA</scp>â€<scp>DQA</scp>1â€<scp>HLA</scp>â€<scp>DRB</scp>1 polymorphism is a major predictor of azathioprineâ€induced pancreatitis in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 615-620.	1.9	53
38	Personalized Anticoagulation: Guided Apixaban Dose Adjustment to Compensate for Pharmacokinetic Abnormalities Related to Short-Bowel Syndrome. Canadian Journal of Cardiology, 2018, 34, 342.e17-342.e19.	0.8	10
39	Letter: predicting azathioprineâ€associated pancreatitis in <scp>IBD</scp>â€”phenotype or genotype? Authors' reply. Alimentary Pharmacology and Therapeutics, 2018, 47, 1044-1045.	1.9	0
40	Food Effect on Rosuvastatin Disposition and Lowâ€Density Lipoprotein Cholesterol. Clinical Pharmacology and Therapeutics, 2018, 104, 525-533.	2.3	9
41	A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia. Blood Advances, 2018, 2, 1935-1945.	2.5	34
42	SLC6A3 Polymorphism Predisposes to Dopamine Overdose in Parkinson's Disease. Frontiers in Neurology, 2018, 9, 693.	1.1	12
43	CYP2D6 genotype and endoxifen plasma concentration do not predict hot flash severity during tamoxifen therapy. Breast Cancer Research and Treatment, 2018, 171, 701-708.	1.1	10
44	Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance. Clinical Pharmacology and Therapeutics, 2018, 104, 890-899.	2.3	185
45	Letrozole concentration is associated with CYP2A6 variation but not with arthralgia in patients with breast cancer. Breast Cancer Research and Treatment, 2018, 172, 371-379.	1.1	9
46	Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas. Histochemistry and Cell Biology, 2017, 148, 345-357.	0.8	10
47	Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. Canadian Journal of Cardiology, 2017, 33, 1036-1043.	0.8	52
48	CYP3A4 Activity is Markedly Lower in Patients with CrohnÊ¼s Disease. Inflammatory Bowel Diseases, 2017, 23, 804-813.	0.9	20
49	Identification and Characterization of Trimethylamine-N-oxide Uptake and Efflux Transporters. Molecular Pharmaceutics, 2017, 14, 310-318.	2.3	53
50	Statin therapy: time for a precision medicine approach?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 187-192.	0.4	1
51	Contribution of Organic Anion-Transporting Polypeptides 1A/1B to Doxorubicin Uptake and Clearance. Molecular Pharmacology, 2017, 91, 14-24.	1.0	33
52	Genetic Determinants of Clozapine-Induced Metabolic Side Effects. Canadian Journal of Psychiatry, 2017, 62, 138-149.	0.9	29
53	Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 149-156.	1.5	20
54	Introduction to Clinical Pharmacology. , 2017, , 365-388.		15

#	Article	IF	Citations
55	Pharmacogenomics Guided-Personalization of Warfarin and Tamoxifen. Journal of Personalized Medicine, 2017, 7, 20.	1.1	12
56	Trimethylamine-N-oxide. Current Opinion in Lipidology, 2016, 27, 148-154.	1.2	62
57	Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome <scp>P</scp>450 3<scp>A</scp> Activity and Singleâ€Timeâ€Point Oral Midazolam Microdose Phenotype in Healthy Subjects. Basic and Clinical Pharmacology and Toxicology, 2016, 118, 284-291.	1.2	25
58	Advanced chronic kidney disease populations have elevated trimethylamine N-oxide levels associated with increased cardiovascular events. Kidney International, 2016, 89, 1144-1152.	2.6	139
59	A Fibroblast Growth Factor 21â€“Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease. Molecular Pharmacology, 2016, 90, 437-446.	1.0	22
60	Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?. Journal of Clinical Pharmacology, 2016, 56, S40-58.	1.0	9
61	Home- vs. Laboratory-Based Management Of OSA: An Economic Review. Current Sleep Medicine Reports, 2016, 2, 107-113.	0.7	7
62	Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFÎ± biologic for ulcerative colitis: a case report. BMC Cancer, 2016, 16, 304.	1.1	10
63	Statin Safety in Chinese: A Population-Based Study of Older Adults. PLoS ONE, 2016, 11, e0150990.	1.1	17
64	Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy. Therapeutic Drug Monitoring, 2015, 37, 428-436.	1.0	64
65	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. American Journal of Gastroenterology, 2015, 110, S773.	0.2	0
66	Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Cmaj, 2015, 187, 174-180.	0.9	54
67	The Impact of Obesity on the Pharmacology of Medications Used for Cardiovascular Risk Factor Control. Canadian Journal of Cardiology, 2015, 31, 167-176.	0.8	28
68	OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy. British Journal of Cancer, 2015, 112, 857-865.	2.9	67
69	Prediction of Renal Transporter Mediated Drug-Drug Interactions for Pemetrexed Using Physiologically Based Pharmacokinetic Modeling. Drug Metabolism and Disposition, 2015, 43, 325-334.	1.7	47
70	Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2015, 60, 3620-3630.	1.1	66
71	Contribution of Hepatic Organic Anion-Transporting Polypeptides to Docetaxel Uptake and Clearance. Molecular Cancer Therapeutics, 2015, 14, 994-1003.	1.9	31
72	SLC transporters as therapeutic targets: emerging opportunities. Nature Reviews Drug Discovery, 2015, 14, 543-560.	21.5	584

#	Article	IF	Citations
73	In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice. Drug Metabolism and Disposition, 2015, 43, 1646-1654.	1.7	10
74	CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition, 2015, 43, 1484-1490.	1.7	103
75	Is personalized medicine a dream or a reality?. Critical Reviews in Clinical Laboratory Sciences, 2015, 52, 1-11.	2.7	24
76	Emerging from the Shadows: A Possible Link between Sleep Apnea and Cancer. Journal of Clinical Sleep Medicine, 2014, 10, 363-364.	1.4	7
77	Ontogeny of Human Hepatic and Intestinal Transporter Gene Expression during Childhood: Age Matters. Drug Metabolism and Disposition, 2014, 42, 1268-1274.	1.7	124
78	Unintended Consequences of Therapy in the Intensive Care Unit. JAMA Internal Medicine, 2014, 174, 574.	2.6	0
79	Organic Cation Transporter Variation and Response to Smoking Cessation Therapies. Nicotine and Tobacco Research, 2014, 16, 1638-1646.	1.4	21
80	Solute Carriers. Cancer Drug Discovery and Development, 2014, , 401-442.	0.2	0
81	Profound reduction in the tamoxifen active metabolite endoxifen in a patient on phenytoin for epilepsy compared with a CYP2D6 genotype matched cohort. Pharmacogenetics and Genomics, 2014, 24, 367-369.	0.7	14
82	Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22. Breast Cancer Research and Treatment, 2014, 145, 419-428.	1.1	26
83	Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease. American Journal of Gastroenterology, 2014, 109, 994-1004.	0.2	50
84	Personalized medicine: importance of clinical interpretative skills for real-world patient care. Personalized Medicine, 2014, 11, 395-408.	0.8	0
85	Clinical performance of bleeding risk scores for predicting major and clinically relevant nonâ€major bleeding events in patients receiving warfarin. Journal of Thrombosis and Haemostasis, 2013, 11, 1647-1654.	1.9	32
86	Determination of clinically therapeutic endoxifen concentrations based on efficacy from human MCF7 breast cancer xenografts. Breast Cancer Research and Treatment, 2013, 139, 61-69.	1.1	31
87	Incremental Lowering of Low-Density Lipoprotein Cholesterol With Ezetimibe 20 mg vs 10 mg Daily in Patients Receiving Concomitant Statin Therapy. Canadian Journal of Cardiology, 2013, 29, 1395-1399.	0.8	4
88	The transfer of pravastatin in the dually perfused human placenta. Placenta, 2013, 34, 719-721.	0.7	34
89	Efficacy and Plasma Drug Concentrations With Nondaily Dosing of Rosuvastatin. Canadian Journal of Cardiology, 2013, 29, 915-919.	0.8	10
90	Pharmacokinetic profiles for oral and subcutaneous methotrexate in patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2013, 37, 340-345.	1.9	30

#	Article	IF	Citations
91	CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy. Breast Cancer Research and Treatment, 2013, 139, 95-105.	1.1	65
92	Pharmacogenetic Advances in Cardiovascular Medicine: Relevance to Personalized Medicine. Current Genetic Medicine Reports, 2013, 1, 1-14.	1.9	4
93	Importance of Pharmacokinetic Profile and Variability as Determinants of Dose and Response to Dabigatran, Rivaroxaban, and Apixaban. Canadian Journal of Cardiology, 2013, 29, S24-S33.	0.8	162
94	Impact of Genetic Variation in OATP Transporters to Drug Disposition and Response. Drug Metabolism and Pharmacokinetics, 2013, 28, 4-18.	1.1	108
95	Sunny outlook for personalized medicine: tamoxifen and beyond. Pharmacogenomics, 2013, 14, 1533-1536.	0.6	0
96	Clinical and Pharmacogenetic Predictors of Circulating Atorvastatin and Rosuvastatin Concentrations in Routine Clinical Care. Circulation: Cardiovascular Genetics, 2013, 6, 400-408.	5.1	168
97	Transport Function and Transcriptional Regulation of a Liver-Enriched Human Organic Anion Transporting Polypeptide 2B1 Transcriptional Start Site Variant. Molecular Pharmacology, 2013, 83, 1218-1228.	1.0	29
98	Ciprofloxacin and Rifampin Have Opposite Effects on Levothyroxine Absorption. Thyroid, 2013, 23, 1374-1378.	2.4	19
99	Absence of both <scp>MDR</scp>1 (<scp>ABCB</scp>1) and Breast Cancer Resistance Protein (<scp>ABCG</scp>2) Transporters Significantly Alters Rivaroxaban Disposition and Central Nervous System Entry. Basic and Clinical Pharmacology and Toxicology, 2013, 112, 164-170.	1.2	41
100	Genetic and clinical determinants of CYP3A4 activity in patients using 4Î²â€hydroxycholesterol as an in vivo probe. FASEB Journal, 2013, 27, 672.3.	0.2	0
101	Regulation of Cytochrome P450 3A4 in Nonâ€Alcoholic Fatty Liver Disease by Fibroblast Growth Factor 21. FASEB Journal, 2013, 27, lb537.	0.2	2
102	Application of a genomicsâ€guided warfarin dosing nomogram for hospitalized patients. FASEB Journal, 2013, 27, 673.1.	0.2	0
103	Disposition of Atorvastatin, Rosuvastatin, and Simvastatin in Oatp1b2â€/â€Mice and Intraindividual Variability in Human Subjects. Journal of Clinical Pharmacology, 2012, 52, 1689-1697.	1.0	27
104	Interaction of Three Regiospecific Amino Acid Residues Is Required for OATP1B1 Gain of OATP1B3 Substrate Specificity. Molecular Pharmaceutics, 2012, 9, 986-995.	2.3	21
105	In Vitro and In Vivo Assessment of Renal Drug Transporters in the Disposition of Mesna and Dimesna. Journal of Clinical Pharmacology, 2012, 52, 530-542.	1.0	28
106	Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants. Expert Opinion on Drug Metabolism and Toxicology, 2012, 8, 709-722.	1.5	4
107	Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. European Heart Journal, 2012, 33, 2856-2864.	1.0	64
108	Drug Transporters in Drug Efficacy and Toxicity. Annual Review of Pharmacology and Toxicology, 2012, 52, 249-273.	4.2	308

#	Article	IF	Citations
109	Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation. Biochemical Pharmacology, 2012, 84, 104-112.	2.0	48
110	Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood, 2011, 118, 3163-3171.	0.6	81
111	Functional analysis of nonsynonymous single nucleotide polymorphisms of multidrug resistance-associated protein 2 (ABCC2). Pharmacogenetics and Genomics, 2011, 21, 506-515.	0.7	28
112	Functional characterization of genetic variants in the apical sodiumâ€dependent bile acid transporter (ASBT; SLC10A2). Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 1740-1748.	1.4	25
113	Use of Transgenic and Knockout Mouse Models to Assess Solute Carrier Transporter Function. Clinical Pharmacology and Therapeutics, 2011, 89, 612-616.	2.3	15
114	Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2. Clinical Pharmacology and Therapeutics, 2011, 89, 816-820.	2.3	53
115	Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis. Hepatology, 2011, 54, 644-654.	3.6	20
116	Endoxifen, the Active Metabolite of Tamoxifen, Is a Substrate of the Efflux Transporter P-Glycoprotein (Multidrug Resistance 1). Drug Metabolism and Disposition, 2011, 39, 558-562.	1.7	65
117	Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. Pharmacogenetics and Genomics, 2011, 21, 103-114.	0.7	79
118	Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation. PLoS ONE, 2011, 6, e27808.	1.1	62
119	Polymorphic variants in the human bile salt export pump (BSEP; ABCB11): functional characterization and interindividual variability. Pharmacogenetics and Genomics, 2010, 20, 45-57.	0.7	60
120	Liver X receptor Î± and farnesoid X receptor are major transcriptional regulators of OATP1B1. Hepatology, 2010, 52, 1797-1807.	3.6	68
121	Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1. British Journal of Pharmacology, 2010, 161, 1023-1033.	2.7	5
122	Membrane transporters in drug development. Nature Reviews Drug Discovery, 2010, 9, 215-236.	21.5	2,886
123	The human proton-coupled folate transporter (hPCFT): modulation of intestinal expression and function by drugs. American Journal of Physiology - Renal Physiology, 2010, 298, G248-G254.	1.6	41
124	Human Skeletal Muscle Drug Transporters Determine Local Exposure and Toxicity of Statins. Circulation Research, 2010, 106, 297-306.	2.0	171
125	Durable Complete Response of Refractory, Progressing Metastatic Melanoma After Treatment with a Patient-Specific Vaccine. Cancer Biotherapy and Radiopharmaceuticals, 2010, 25, 553-557.	0.7	22
126	Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. American Journal of Physiology - Renal Physiology, 2010, 298, F997-F1005.	1.3	122

#	Article	IF	Citations
127	Introduction to Clinical Pharmacology. , 2009, , 321-338.		2
128	Personalized medicine and antiplatelet therapy: ready for prime time?. European Heart Journal, 2009, 30, 1943-1963.	1.0	37
129	Hepatic drug transporters, old and new: Pharmacogenomics, drug response, and clinical relevance. Hepatology, 2009, 50, 1014-1016.	3.6	15
130	Bloodâ˜brain barrier transporters and response to CNS-active drugs. European Journal of Clinical Pharmacology, 2009, 65, 1063-1070.	0.8	161
131	Identification, Expression, and Functional Characterization of Full-Length and Splice Variants of Murine Organic Anion Transporting Polypeptide 1b2. Molecular Pharmaceutics, 2009, 6, 1790-1797.	2.3	16
132	Hepatic OATP1B Transporters and Nuclear Receptors PXR and CAR: Interplay, Regulation of Drug Disposition Genes, and Single Nucleotide Polymorphisms. Molecular Pharmaceutics, 2009, 6, 1644-1661.	2.3	53
133	The Organic Cation Transporter, OCTN1, Expressed in the Human Heart, Potentiates Antagonism of the HERG Potassium Channel. Journal of Cardiovascular Pharmacology, 2009, 54, 63-71.	0.8	34
134	Drug Transporters. , 2009, , 45-84.		3
135	Pharmacogenomics of MRP Transporters (ABCC1-5) and BCRP (ABCG2). Drug Metabolism Reviews, 2008, 40, 317-354.	1.5	102
136	Genetic Determinants of Response to Warfarin during Initial Anticoagulation. New England Journal of Medicine, 2008, 358, 999-1008.	13.9	516
137	Overexpression of OATP1B3 Confers Apoptotic Resistance in Colon Cancer. Cancer Research, 2008, 68, 10315-10323.	0.4	122
138	Interplay between the Nuclear Receptor Pregnane X Receptor and the Uptake Transporter Organic Anion Transporter Polypeptide 1A2 Selectively Enhances Estrogen Effects in Breast Cancer. Cancer Research, 2008, 68, 9338-9347.	0.4	117
139	Transporter-Mediated Protection against Thiopurine-Induced Hematopoietic Toxicity. Cancer Research, 2008, 68, 4983-4989.	0.4	124
140	A Human Immunodeficiency Virus Protease Inhibitor Is a Novel Functional Inhibitor of Human Pregnane X Receptor. Drug Metabolism and Disposition, 2008, 36, 500-507.	1.7	67
141	Targeted Disruption of Murine Organic Anion-Transporting Polypeptide 1b2 (oatp1b2/Slco1b2) Significantly Alters Disposition of Prototypical Drug Substrates Pravastatin and Rifampin. Molecular Pharmacology, 2008, 74, 320-329.	1.0	109
142	Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. Pharmacogenetics and Genomics, 2008, 18, 439-448.	0.7	120
143	Human MRP2 polymorphisms and their impact on substrate transport. FASEB Journal, 2008, 22, 1132.4.	0.2	0
144	Expression and functional characterization of murine organic anion transporting polypeptide 1b2 (oatp1b2/oatp4/lstâ€1). FASEB Journal, 2008, 22, 1132.5.	0.2	0

#	Article	IF	Citations
145	A Common Polymorphism in the Bile Acid Receptor Farnesoid X Receptor Is Associated with Decreased Hepatic Target Gene Expression. Molecular Endocrinology, 2007, 21, 1769-1780.	3.7	61
146	Differential Inhibition of Rat and Human Na+-Dependent Taurocholate Cotransporting Polypeptide (NTCP/SLC10A1)by Bosentan: A Mechanism for Species Differences in Hepatotoxicity. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 1170-1178.	1.3	119
147	Defining the Cellular Phenotype of â€œAnkyrin-B Syndromeâ€•Variants. Circulation, 2007, 115, 432-441.	1.6	161
148	Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenetics and Genomics, 2007, 17, 647-656.	0.7	172
149	Nuclear Receptors and the Regulation of Drug-Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs. Journal of Clinical Pharmacology, 2007, 47, 566-578.	1.0	328
150	Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans. Clinical Pharmacology and Therapeutics, 2007, 81, 362-370.	2.3	374
151	Naringin is a Major and Selective Clinical Inhibitor of Organic Anion-Transporting Polypeptide 1A2 (OATP1A2) in Grapefruit Juice. Clinical Pharmacology and Therapeutics, 2007, 81, 495-502.	2.3	252
152	Induction of Intestinal P-glycoprotein by St John's Wort Reduces the Oral Bioavailability of Talinolol. Clinical Pharmacology and Therapeutics, 2007, 81, 669-678.	2.3	131
153	Transporters and Drug Discovery:â€‰ Why, When, and How. Molecular Pharmaceutics, 2006, 3, 26-32.	2.3	77
154	Drug and Bile Acid Transporters in Rosuvastatin Hepatic Uptake: Function, Expression, and Pharmacogenetics. Gastroenterology, 2006, 130, 1793-1806.	0.6	542
155	Inability to Upregulate Cytochrome P450 4A and 2C Causes Salt Sensitivity in Young Sprague-Dawley Rats. American Journal of Hypertension, 2006, 19, 1174-1180.	1.0	17
156	Multilocus genetic interactions and response to efavirenz-containing regimens: an Adult AIDS Clinical Trials Group study. Pharmacogenetics and Genomics, 2006, 16, 837-845.	0.7	59
157	Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. British Journal of Clinical Pharmacology, 2006, 62, 485-491.	1.1	23
158	Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clinical Pharmacology and Therapeutics, 2006, 79, 186-196.	2.3	87
159	OII-B-1The role of NA+-taurocholate cotransporting polypeptide (NTCP) in the hepatic uptake of rosuvastatin. Clinical Pharmacology and Therapeutics, 2006, 79, P5-P5.	2.3	0
160	PI-32The effects of folate supplementation on human CYP2C9 transactivation. Clinical Pharmacology and Therapeutics, 2006, 79, P15-P15.	2.3	1
161	PI-50OATP1A2 is the major uptake transporter of fexofenadine in humans. Clinical Pharmacology and Therapeutics, 2006, 79, P20-P20.	2.3	2
162	PIII-26Hepatic nuclear factor (HNF)1Î±activates the induction of human CYP2C9 by rifampin (Rif) and interacts with HNF4Î± and small heterodimer partner 1 (SHP-1). Clinical Pharmacology and Therapeutics, 2006, 79, P65-P65.	2.3	1

#	Article	IF	Citations
163	Transactivation of Rat Apical Sodium-Dependent Bile Acid Transporter and Increased Bile Acid Transport by 1Î±,25-Dihydroxyvitamin D3 via the Vitamin D Receptor. Molecular Pharmacology, 2006, 69, 1913-1923.	1.0	73
164	Pharmacogenetics of Plasma Efavirenz Exposure after Treatment Discontinuation: An Adult AIDS Clinical Trials Group Study. Clinical Infectious Diseases, 2006, 42, 401-407.	2.9	208
165	Ritonavir, Saquinavir, and Efavirenz, but Not Nevirapine, Inhibit Bile Acid Transport in Human and Rat Hepatocytes. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1068-1075.	1.3	98
166	Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity. Clinical Infectious Diseases, 2006, 43, 779-782.	2.9	91
167	Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration. Clinical Infectious Diseases, 2006, 43, 783-786.	2.9	131
168	The Relevance of Transporters in Determining Drug Disposition. , 2006, , 423-459.		0
169	Differential in Vivo Sensitivity to Inhibition of P-glycoprotein Located in Lymphocytes, Testes, and the Blood-Brain Barrier. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 1012-1018.	1.3	78
170	Effect of Grapefruit Juice Volume on the Reduction of Fexofenadine Bioavailability: Possible Role of Organic Anion Transporting Polypeptides*. Clinical Pharmacology and Therapeutics, 2005, 77, 170-177.	2.3	176
171	Polymorphism Screening in the Cardiac K+ Channel Gene KCNA5*. Clinical Pharmacology and Therapeutics, 2005, 77, 138-144.	2.3	41
172	Grapefruit juice ingestion reduces talinolol serum concentration. Clinical Pharmacology and Therapeutics, 2005, 77, P4-P4.	2.3	0
173	Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clinical Pharmacology and Therapeutics, 2005, 77, 291-301.	2.3	138
174	Effects of infant formula, cow milk and human milk on drug metabolizing enzymes. Clinical Pharmacology and Therapeutics, 2005, 77, P46-P46.	2.3	0
175	Multiple OATP transporters mediate the cellular uptake of rosuvastatin. Clinical Pharmacology and Therapeutics, 2005, 77, P64-P64.	2.3	4
176	St Johnâ€™s wort-associated drug interactions: Short-term inhibition and long-term induction?. Clinical Pharmacology and Therapeutics, 2005, 78, 19-24.	2.3	44
177	Transporters and drug therapy: Implications for drug disposition and disease. Clinical Pharmacology and Therapeutics, 2005, 78, 260-277.	2.3	425
178	Induction of cytochrome P450 1A by cow milk-based formula: a comparative study between human milk and formula. British Journal of Pharmacology, 2005, 146, 296-305.	2.7	21
179	Nuclear Receptors and Drug Disposition Gene Regulation. Journal of Pharmaceutical Sciences, 2005, 94, 1169-1186.	1.6	176
180	Beyond CAR and PXR. Current Drug Metabolism, 2005, 6, 385-397.	0.7	33

#	Article	IF	Citations
181	HEPATIC UPTAKE OF THE NOVEL ANTIFUNGAL AGENT CASPOFUNGIN. Drug Metabolism and Disposition, 2005, 33, 676-682.	1.7	105
182	Polymorphisms in Human Organic Anion-transporting Polypeptide 1A2 (OATP1A2). Journal of Biological Chemistry, 2005, 280, 9610-9617.	1.6	316
183	Cancer Pharmacogenomics: Powerful Tools in Cancer Chemotherapy and Drug Development. Oncologist, 2005, 10, 104-111.	1.9	116
184	Pharmacogenetics of Longâ€Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study. Journal of Infectious Diseases, 2005, 192, 1931-1942.	1.9	232
185	Pharmacogenetics of Drug Transporters. Drugs and the Pharmaceutical Sciences, 2005, , 109-155.	0.1	2
186	Identification of Amino Acids in Rat Pregnane X Receptor that Determine Species-Specific Activation. Molecular Pharmacology, 2004, 65, 36-44.	1.0	76
187	Ethnicity-dependent Polymorphism in Na+-taurocholate Cotransporting Polypeptide (SLC10A1) Reveals a Domain Critical for Bile Acid Substrate Recognition. Journal of Biological Chemistry, 2004, 279, 7213-7222.	1.6	167
188	P-glycoprotein Expression, Localization, and Function in Sandwich-Cultured Primary Rat and Human Hepatocytes: Relevance to the Hepatobiliary Disposition of a Model Opioid Peptide. Pharmaceutical Research, 2004, 21, 1294-1302.	1.7	136
189	TRANSPORTERS ANDRENALDRUGELIMINATION. Annual Review of Pharmacology and Toxicology, 2004, 44, 137-166.	4.2	210
190	Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clinical Pharmacology and Therapeutics, 2004, 75, 13-33.	2.3	781
191	Evaluation of ethnicity, gender, and OATP-C genotypes as determinants of pravastatin disposition. Clinical Pharmacology and Therapeutics, 2004, 75, P66.	2.3	0
192	A common polymorphism in the adenylyl cyclase type 9 (AC9) gene does not alter vascular responses to isoproterenol. Clinical Pharmacology and Therapeutics, 2004, 75, P70.	2.3	0
193	Evaluation of herbal products as potential inhibitors of MDR1. Clinical Pharmacology and Therapeutics, 2004, 75, P79.	2.3	6
194	Identification of nonsynonomous polymorphisms of human organic anion transporting polypeptide-A (OATP-A) associated with altered transport activity. Clinical Pharmacology and Therapeutics, 2004, 75, P93.	2.3	2
195	3-Hydroxy-3-methylglutarylâ€“coenzyme a reductase inhibitors (statins) and genetic variability (single) Tj ETQq1 1 0.784314 rgBT /Ov Pharmacology and Therapeutics, 2004, 75, 381-385.	2.3	46
196	$alpha;1A-adrenergic receptor polymorphism and vascular response*1, *2. Clinical Pharmacology and Therapeutics, 2004, 75, 539-545.	2.3	23
197	Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics, 2004, 5, 243-272.	0.6	261
198	Pharmacogenomics of the OATP and OAT families. Pharmacogenomics, 2004, 5, 273-282.	0.6	117

#	Article	IF	Citations
199	Î²2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Pharmacogenetics and Genomics, 2004, 14, 517-522.	5.7	54
200	Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clinical Pharmacology and Therapeutics, 2003, 73, 41-50.	2.3	223
201	Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clinical Pharmacology and Therapeutics, 2003, 73, 253-263.	2.3	174
202	Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. Toxicology and Applied Pharmacology, 2003, 186, 119-126.	1.3	26
203	A common Î²1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to Î²-blockade. Clinical Pharmacology and Therapeutics, 2003, 73, 366-371.	2.3	145
204	â€œInactiveâ€•excipients such as Cremophor can affect in vivo drug disposition. Clinical Pharmacology and Therapeutics, 2003, 73, 394-396.	2.3	64
205	Stable and tightly regulated expression of human NA+ taurocholate cotransporting polypeptide (NTCP) using a tetracycline-inducible system.. Clinical Pharmacology and Therapeutics, 2003, 73, P13-P13.	2.3	0
206	Duration of Grapefruit Juice Effect on Fexofenadine Interaction. Clinical Pharmacology and Therapeutics, 2003, 73, P48-P48.	2.3	2
207	Identification of a new beta1-adrenergic receptor variant VAL5ALA more frequent in African-Americans.. Clinical Pharmacology and Therapeutics, 2003, 73, P97-P97.	2.3	0
208	Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. European Journal of Clinical Investigation, 2003, 33, 1-5.	1.7	169
209	Antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating membrane steroid transporters. British Journal of Pharmacology, 2003, 139, 1111-1118.	2.7	83
210	The orphan nuclear receptor HNF4Î± determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nature Medicine, 2003, 9, 220-224.	15.2	418
211	Human Organic Anion Transporting Polypeptide-C (SLC21A6) Is a Major Determinant of Rifampin-Mediated Pregnane X Receptor Activation. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 223-228.	1.3	302
212	The Human Organic Anion Transport Protein SLC21A6 Is Not Sufficient for Bilirubin Transport. Journal of Biological Chemistry, 2003, 278, 20695-20699.	1.6	79
213	MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 34, 295-298.	0.9	54
214	Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics and Genomics, 2003, 13, 595-606.	5.7	238
215	Development of A Real-Time in Vivo Transcription Assay: Application Reveals Pregnane X Receptor-Mediated Induction of CYP3A4 by Cancer Chemotherapeutic Agents. Molecular Pharmacology, 2002, 62, 439-445.	1.0	51
216	Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein. Anesthesiology, 2002, 96, 913-920.	1.3	205

#	Article	IF	Citations
217	MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. Pharmacogenetics and Genomics, 2002, 12, 425-427.	5.7	84
218	Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates. Molecular Pharmacology, 2002, 61, 974-981.	1.0	204
219	The Anthelminthic Agent Albendazole Does Not Interact with P-Glycoprotein. Drug Metabolism and Disposition, 2002, 30, 365-369.	1.7	43
220	Three-Dimensional Quantitative Structure-Activity Relationships of Inhibitors of P-Glycoprotein. Molecular Pharmacology, 2002, 61, 964-973.	1.0	179
221	CYP2C9 allelic variants: ethnic distribution and functional significance. Advanced Drug Delivery Reviews, 2002, 54, 1257-1270.	6.6	309
222	Pharmacogenomics of organic anion-transporting polypeptides (OATP). Advanced Drug Delivery Reviews, 2002, 54, 1343-1352.	6.6	111
223	Pharmacogenetics of CYP enzymes and drug transporters: remarkable recent advances. Advanced Drug Delivery Reviews, 2002, 54, 1241-1242.	6.6	14
224	Polymorphisms in Beta-Adrenergic Receptor Genes in the Acquired Long QT Syndrome. Journal of Cardiovascular Electrophysiology, 2002, 13, 252-256.	0.8	36
225	Transporters and xenobiotic disposition. Toxicology, 2002, 181-182, 291-297.	2.0	78
226	Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metabolism Reviews, 2002, 34, 47-54.	1.5	336
227	Transport of the sulfated, amidated bile acid, sulfolithocholyltaurine, into rat hepatocytes is mediated by Oatp1 and Oatp2. Hepatology, 2002, 35, 1031-1040.	3.6	22
228	Fruit juices inhibit organic anion transporting polypeptideâ€“mediated drug uptake to decrease the oral availability of fexofenadine. Clinical Pharmacology and Therapeutics, 2002, 71, 11-20.	2.3	538
229	Site-Directed Mutagenesis Studies on a Putative Fifth Iron Ligand of Mouse 8S-Lipoxygenase: Retention of Catalytic Activity on Mutation of Serine-558 to Asparagine, Histidine, or Alanine. Archives of Biochemistry and Biophysics, 2001, 386, 136-142.	1.4	8
230	The Effect of Common Polymorphisms of the Î²2-Adrenergic Receptor on Agonist-Mediated Vascular Desensitization. New England Journal of Medicine, 2001, 345, 1030-1035.	13.9	344
231	MOLECULARBASIS OFETHNICDIFFERENCES INDRUGDISPOSITION ANDRESPONSE. Annual Review of Pharmacology and Toxicology, 2001, 41, 815-850.	4.2	552
232	Identification and Functional Characterization of a New CYP2C9 Variant (CYP2C9*5) Expressed among African Americans. Molecular Pharmacology, 2001, 60, 382-387.	1.0	268
233	The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics and Genomics, 2001, 11, 555-572.	5.7	293
234	Arg389Gly ??1-adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response in vivo. Pharmacogenetics and Genomics, 2001, 11, 191-197.	5.7	100

#	Article	IF	Citations
235	In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. Pharmacogenetics and Genomics, 2001, 11, 809-814.	5.7	47
236	Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clinical Pharmacology and Therapeutics, 2001, 69, 317-323.	2.3	31
237	Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clinical Pharmacology and Therapeutics, 2001, 70, 189-199.	2.3	883
238	Polymorphisms in OATP-C. Journal of Biological Chemistry, 2001, 276, 35669-35675.	1.6	558
239	Disrupted Bile Acid Homeostasis Reveals an Unexpected Interaction among Nuclear Hormone Receptors, Transporters, and Cytochrome P450. Journal of Biological Chemistry, 2001, 276, 39411-39418.	1.6	343
240	Human Î²2-adrenergic receptor polymorphisms: No association with essential hypertension in black or white Americans. Clinical Pharmacology and Therapeutics, 2000, 67, 670-675.	2.3	70
241	Drug efflux transporters and antiviral drug therapy. Expert Opinion on Therapeutic Targets, 2000, 4, 439-446.	1.0	0
242	Identification of Amino Acid Determinants of the Positional Specificity of Mouse 8S-Lipoxygenase and Human 15S-Lipoxygenase-2. Journal of Biological Chemistry, 2000, 275, 1287-1293.	1.6	94
243	Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. Molecular Pharmacology, 2000, 57, 24-35.	1.0	90
244	Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metabolism and Disposition, 2000, 28, 655-60.	1.7	286
245	Transporters and drug disposition. Current Opinion in Drug Discovery & Development, 2000, 3, 94-101.	1.9	5
246	Inhibition of P-Glycoproteinâ€“Mediated Drug Transport. Circulation, 1999, 99, 552-557.	1.6	407
247	Genetic polymorphism of (S)-mephenytoin 4â€²-hydroxylation in populations of African descent. British Journal of Clinical Pharmacology, 1999, 48, 402-408.	1.1	49
248	Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A*. Clinical Pharmacology and Therapeutics, 1999, 66, 224-231.	2.3	123
249	Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmaceutical Research, 1999, 16, 408-414.	1.7	404
250	Human MRP3 transporter: identification of the 5â€²-flanking region, genomic organization and alternative splice variants1The GenBank accession numbers of MRP3 and its splice variants MRP3A and MRP3B described in this paper are AF085690, AF085691 and AF085692, respectively.1. Biochimica Et Biophysica Acta - Biomembranes, 1999, 1415, 369-374.	1.4	39
251	Allelic, genotypic and phenotypic distributions of S-mephenytoin 4???-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics and Genomics, 1999, 9, 539-550.	5.7	164
252	??1A-Adrenergic receptor polymorphism. Pharmacogenetics and Genomics, 1999, 9, 651-656.	5.7	48

#	Article	IF	Citations
253	Allelic, genotypic and phenotypic distributions of S-mephenytoin 4???-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics and Genomics, 1999, 9, 539-550.	0.7	1
254	OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metabolism and Disposition, 1999, 27, 866-71.	1.7	468
255	P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Research, 1999, 59, 3944-8.	0.4	194
256	Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate) Tj ETQq0 0 0 rgBT /Overlock 10 T 291, 1204-9.	1.3	76
257	Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics and Genomics, 1999, 9, 511-6.	5.7	75
258	Modulation by Dietary Salt of Verapamil Disposition in Humans. Circulation, 1998, 98, 2702-2708.	1.6	31
259	A 12R-lipoxygenase in human skin: Mechanistic evidence, molecular cloning, and expression. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 6744-6749.	3.3	157
260	The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.. Journal of Clinical Investigation, 1998, 101, 289-294.	3.9	931
261	Molecular Cloning and Functional Expression of a Phorbol Ester-inducible 8S-Lipoxygenase from Mouse Skin. Journal of Biological Chemistry, 1997, 272, 24410-24416.	1.6	101
262	High affinity uptake by isolated rat hepatocytes of a linear pseudo-hexapeptide, ditekiren. Biochimica Et Biophysica Acta - Biomembranes, 1997, 1328, 41-47.	1.4	3
263	Modulation of CYP2EI activity by isoniazid in rapid and slow Nâ€acetylators. British Journal of Clinical Pharmacology, 1997, 43, 99-103.	1.1	10
264	Modulation of CYP2EI activity by isoniazid in rapid and slow N-acetylators. British Journal of Clinical Pharmacology, 1997, 43, 99-103.	1.1	28
265	Characterization of the hepatic canalicular membrane transport of a model oligopeptide: ditekiren. Journal of Pharmacology and Experimental Therapeutics, 1997, 281, 297-303.	1.3	12
266	CYP2E1 activity is not altered by influenza vaccination. British Journal of Clinical Pharmacology, 1996, 42, 529-530.	1.1	11
267	In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. Journal of Pharmacology and Experimental Therapeutics, 1996, 279, 4-11.	1.3	66
268	Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms*. Clinical Pharmacology and Therapeutics, 1995, 57, 645-655.	2.3	143
269	Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: A putative probe of CYP2E1 activity. Clinical Pharmacology and Therapeutics, 1994, 56, 359-367.	2.3	191
270	Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: a putative measure of CYP2E1 activity. Pharmacogenetics and Genomics, 1994, 4, 162-5.	5.7	18

#	Article	IF	Citations
271	Pharmacogenomics of Drug Transporters. , 0, , 179-213.		5
272	Organic Anionâ€“Transporting Polypeptides. , 0, , 75-104.		7
273	Nuclear Receptors and Drugâ€“Drug Interactions with Prescription and Herbal Medicines. , 0, , 211-239.		0